Teplizumab

替利珠单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameTeplizumab
Drug Alias NameTeplizumabum特普利珠单抗TeraplizumabTeplizumab-mzwvTZIELD +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT cell surface glycoprotein CD3 inhibitors
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsRejection of renal transplantationHypoglycemiaGlucose Intolerance +[6] 
Global Approved IndicationsDiabetes Mellitus, Type 1
Approved Indications in ChinaDiabetes Mellitus, Type 1
Original Approved Country/TerritoryUnited States
Original Approved Date2022/11/17
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[28] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTolerance Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLigand Pharmaceuticals IncSanofiProvention Bio Inc +[4] 
Inactive CompaniesUniversity Of MinnesotaYale UniversityMacrogenics Inc +[8] 
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsRejection of renal transplantationHypoglycemiaGlucose Intolerance +[5] 

Other Information

ATC CodeL01FXL01XC
Related LinksWikipediaDrugBankKEGG